Atizoram

Atizoram (CP-80,633) is an orally active phosphodiesterase type 4 (PDE4) inhibitor. Atizoram blocks cAMP degradation, thereby increasing intracellular and plasma cAMP levels. Atizoram inhibits TNFα release. Atizoram can be used in research related to acute respiratory distress syndrome^[1][2]. In Vitro:Atizoram increases intracellular cAMP levels and inhibits TNFα release from monocytes in vitro^[1]. In Vivo:Atizoram (1-32 mg/kg; p.o.; single dose) administered orally to male Balb/c mice dose-dependently elevates plasma cAMP (with a 6-fold increase at 10 mg/kg p.o.) and epinephrine, with the cAMP effect lasting up to 250 minutes, and propranolol significantly reduces the cAMP response in control mice^[1].
Atizoram (1-30 mg/kg; p.o.; single dose) administered orally dose-dependently inhibits LPS-induced serum TNFα production in mice, with a slight reduction in potency after adrenalectomy (ED₅₀ 1.2 mg/kg p.o. in controls vs. 3.9 mg/kg p.o. in adx mice)^[1].